Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Inventory: 2018-2025

Historic Inventory for Coherus Oncology (CHRS) over the last 7 years, with Sep 2025 value amounting to $2.0 million.

  • Coherus Oncology's Inventory fell 95.70% to $2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.0 million, marking a year-over-year decrease of 95.70%. This contributed to the annual value of $4.2 million for FY2024, which is 93.28% down from last year.
  • Latest data reveals that Coherus Oncology reported Inventory of $2.0 million as of Q3 2025, which was down 54.62% from $4.5 million recorded in Q2 2025.
  • Coherus Oncology's Inventory's 5-year high stood at $66.8 million during Q3 2023, with a 5-year trough of $2.0 million in Q3 2025.
  • Over the past 3 years, Coherus Oncology's median Inventory value was $49.4 million (recorded in 2023), while the average stood at $39.0 million.
  • As far as peak fluctuations go, Coherus Oncology's Inventory soared by 214.02% in 2021, and later slumped by 95.70% in 2025.
  • Quarterly analysis of 5 years shows Coherus Oncology's Inventory stood at $37.6 million in 2021, then increased by 3.05% to $38.8 million in 2022, then surged by 61.39% to $62.6 million in 2023, then plummeted by 93.28% to $4.2 million in 2024, then plummeted by 95.70% to $2.0 million in 2025.
  • Its last three reported values are $2.0 million in Q3 2025, $4.5 million for Q2 2025, and $3.5 million during Q1 2025.